---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-070450"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2024-06-11T23:59:59+00:00"
generated_at: "2026-06-01T05:01:27.492738+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio Buntanetap Phase II/III shows statistically significant efficacy in APOE4 Alzheimer's patients

## Summary
- In early AD patients (MMSE 21-24), Buntanetap showed -3.3 point ADAS-Cog11 improvement vs baseline and -2.3 vs placebo.
- APOE4 carriers on 15mg dose achieved -3.15 point improvement in ADAS-Cog11 scores.
- Buntanetap had no ARIA or serious drug-related TEAEs; safety comparable in carriers and non-carriers.
- Study included 159 APOE4 carriers (33 homozygotes) and 159 non-carriers.
- Company plans 18-month Phase III trial in biomarker-positive early AD patients under FDA guidance.

## SEC filing metadata
- accession: 0001104659-24-070450
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2024-06-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465924070450/0001104659-24-070450-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465924070450/tm2416963d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-070450
- JSON: https://secwatch.observer/filing/0001104659-24-070450.json
- Plain text: https://secwatch.observer/filing/0001104659-24-070450.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.